RESULT: Is Sirtex Medical Limited a jaw-dropping BARGAIN?

Sirtex Medical Limited (ASX:SRX) has reported a jump in dose sales but a fall in profit. Is it cheap?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This morning, Sirtex Medical Limited (ASX:SRX) reported a jump in half-year dose sales but a fall in net profit.

Here are the key takeaways:

  • Revenue rose 0.2% to $112.8 million
  • Profit fell 20% to $20.8 million
  • No dividend was declared
  • Dose sales rose 5.6%
  • A share buyback of $30 million was approved

Sirtex is a $900 million biotechnology company which produces a product called SIR-Spheres. It is a tiny treatment that attacks small blood cells in liver cancer tumours. It is administered by a radiologist.

Sirtex's major markets are:

  • The USA, which reported 4,248 doses – representing growth of 5.5%
  • Europe, the Middle East and Africa (EMEA), which reported 1,269 doses – growth of 4.1%; and
  • Asia Pacific, which had 530 dose sales, up 10.2%

Given the growth in dose sales, revenue held mostly steady during the half despite challenging currency movements.

Sirtex said profit fell as the revenue mix shifted (keep in mind a lot of growth came from Asia), it increased expenditure, and manufacturing costs rose.

Also affecting profit was an increase in marketing expenses and impairments.

Profits per share fell to 35.8 cents per share, from 44.6 cents.

"We are clearly disappointed with the 1H17 financial results in light of the lower than anticipated growth in dose sales," interim CEO, Nigel Lange, said. "However, we have made it our absolute priority to stabilise the business through the appointment of experienced senior executives, initiated a cost cutting program in areas non-core to our SIR-Spheres® Y- 90 resin microspheres business, and importantly recognised our loyal shareholders with a $30 million onmarket share buy-back over the next six months."

Controversy

The Sirtex Medical share price plummeted earlier this year when the market was caught off-guard by a profit downgrade. Former CEO Gilman Wong had his employment terminated following an internal investigation into his sale of company shares.

Subsequently, the company was served with a class action by lawyers and shareholders who allege it misled them. At this stage, Sirtex says it is unable to assess how large the claim could be.

Are Sirtex shares a bargain?

Looking ahead, Sirtex has dropped its three-pillar '2020 Vision' strategy and will focus on SIR-Spheres. It is aiming to cut $7 million in costs, starting from its 2018 financial year. Importantly for investors focused on the short term, it also reiterated its operating profit guidance for the remainder of this financial year. It expects dose sales growth between 5% and 11%, with operating profit of $65 million to $74 million.

At today's prices, Sirtex shares trade on 22 times its profits, which may not exactly be a bargain when we factor in the uncertainty around the lawsuit, management and competitive pressures.

Having said that, Sirtex clearly has a lot of potential and — in my opinion — could be worthy of a small speculative / high-risk investment.

Motley Fool Contributor Owen Raszkiewicz does not have a financial interest in any company mentioned. Owen welcomes and encourages your feedback. You can follow him on Twitter @OwenRask. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »